Apr 25 |
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
|
Apr 24 |
Actym Therapeutics Appoints Thomas Smart as CEO
|
Apr 23 |
Day One wins FDA nod for brain cancer therapy, Ojemda
|
Apr 20 |
XOMA (NASDAQ:XOMA) shareholders have earned a 16% CAGR over the last five years
|
Apr 3 |
XOMA Corporation Announces Closing of Tender Offer
|
Mar 19 |
XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.
|
Mar 8 |
XOMA Corporation files $200M mixed securities shelf
|
Mar 8 |
XOMA Corp (XOMA) Reports Mixed Financial Results for Q4 and Full Year 2023
|
Mar 8 |
Recap: XOMA Q4 Earnings
|
Mar 8 |
XOMA GAAP EPS of -$4.04 misses by $1.99, revenue of $4.76M misses by $1.74M
|